A high-profile squabble at the renowned MD Anderson Cancer Center saw a new twist as Dr. Padmanee Sharma, a leading oncologist, fired back against accusations in a lawsuit claiming she attempted to hijack credit for a younger scientist's research. Legal papers filed on Friday by Sharma's legal team from the Texas Attorney General's Office suggested that not only did Sharma make substantial contributions to the contested immunotherapy study, but a third-party review also backed her claim for credit. According to STAT News, Sharma is squaring off against allegations of career sabotage, defamation, and credit theft, which she vehemently denies.
The conflict revolves around research integral to understanding tertiary lymphoid structures, components in the immune system that could revolutionize cancer treatment. Dr. Jamie Lin, a junior faculty member, has filed suit against Sharma, seeking $5 million in damages, asserting her work was appropriated, according to a report by the Houston Chronicle. Sharma's rebuttal hinges on the protection offered to government employees against such lawsuits for acts conducted in their official capacity, and her attorneys argue for shifting the defendant's name from Sharma to MD Anderson in the lawsuit.
Frustrations escalated when Sharma discovered that her contributions to a study on kidney complications from immunotherapy, which she claims to have mentored Lin through, were allegedly omitted from a manuscript due for submission to Cancer Immunology Research. Sharma's declaration, detailed in the court filing, showed that Sharma insisted on being recognized and informed Lin she would notify the journal of the authorship dispute.
Matters didn't calm when Lin accused the senior researcher of confrontations at Santa Barbara Airport and alleged threats to derail her funding, coupled with defamatory statements to the scientific journal, as detailed by the Houston Chronicle. This lead to MD Anderson commissioning Ropes and Grey LLP to objectively examine the brouhaha, which culminated in an assessment favoring Sharma's demand for recognition in the disputed manuscripts.
Jaws dropped as the battle kept heating up, with Lin further alleging that Sharma sent emails with false plagiarism accusations to the Journal of Clinical Investigation Insight, regarding a second manuscript. Sharma's defense, bolstered by the third-party review findings, now stands as a fortress against Lin's claims, effectively arguing that if one were to look for a villain in this academic drama, it might not be the seasoned immunotherapy expert. As per legal processes, Sharma has now requested the lawsuit be amended or thrown out, a move that will surely intensify the watchful gaze of the scientific community on this high-stakes intellectual property kerfuffle.
